A cell-laden hydrogel as prophylactic vaccine and anti-PD-L1 amplifier against autologous tumors.

[1]  Lian Li,et al.  Trauma-Responsive Scaffold Synchronizing Oncolysis Immunization and Inflammation Alleviation for Post-Operative Suppression of Cancer Metastasis. , 2022, ACS nano.

[2]  F. Meng,et al.  Immunotherapy of Malignant Glioma by Noninvasive Administration of TLR9 Agonist CpG Nano‐Immunoadjuvant , 2022, Advanced science.

[3]  Lian Li,et al.  Immunogenic hydrogel toolkit disturbing residual tumor “seeds” and pre-metastatic “soil” for inhibition of postoperative tumor recurrence and metastasis , 2022, Acta pharmaceutica Sinica. B.

[4]  Redirecting Chemotherapeutics to the Endoplasmic Reticulum Increases Tumor Immunogenicity and Potentiates Anti-PD-L1 Therapy. , 2021, Small.

[5]  J. Lovell,et al.  Peptide hydrogels loaded with irradiated tumor cell secretions enhance cancer immunotherapy , 2021, Nano Today.

[6]  Kanyi Pu,et al.  Bioinspired and Biomimetic Delivery Platforms for Cancer Vaccines , 2021, Advanced materials.

[7]  J. Lovell,et al.  Secretions from hypochlorous acid-treated tumor cells delivered in a melittin hydrogel potentiate cancer immunotherapy , 2021, Bioactive Materials.

[8]  B. Klumperman,et al.  Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[9]  Lian Li,et al.  Improving anti-PD-L1 therapy in triple negative breast cancer by polymer-enhanced immunogenic cell death and CXCR4 blockade. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[10]  J. Kopeček,et al.  Combination treatment with immunogenic and anti-PD-L1 polymer-drug conjugates of advanced tumors in a transgenic MMTV-PyMT mouse model of breast cancer. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[11]  J. Kopeček,et al.  Dendronized polymer conjugates with amplified immunogenic cell death for oncolytic immunotherapy. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[12]  Cory J. Berkland,et al.  Human intratumoral therapy: Linking drug properties and tumor transport of drugs in clinical trials. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[13]  J. Kopeček,et al.  Inhibition of Immunosuppressive Tumors by Polymer‐Assisted Inductions of Immunogenic Cell Death and Multivalent PD‐L1 Crosslinking , 2020, Advanced functional materials.

[14]  Lian Li,et al.  Restoration and Enhancement of Immunogenic Cell Death of Cisplatin by Coadministration with Digoxin and Conjugation to HPMA Copolymer. , 2019, ACS applied materials & interfaces.

[15]  L. Zitvogel,et al.  Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies , 2019, Nature Reviews Clinical Oncology.

[16]  Hao Cheng,et al.  A Dual‐Bioresponsive Drug‐Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade , 2019, Advanced materials.

[17]  Joo Hoon Kim,et al.  Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade , 2018, Clinical Cancer Research.

[18]  A. Mäkitie,et al.  Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[19]  J. Moon,et al.  Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[20]  S. Son,et al.  Elimination of established tumors with nanodisc-based combination chemoimmunotherapy , 2018, Science Advances.

[21]  K. Kabashima,et al.  Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations , 2018, Front. Oncol..

[22]  Michael S. Goldberg,et al.  Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases , 2018, Science Translational Medicine.

[23]  Zhuang Liu,et al.  In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy , 2018, Science Translational Medicine.

[24]  Michael E. Lassman,et al.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy , 2017, Cell.

[25]  Jedd D. Wolchok,et al.  T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.

[26]  Matthieu Texier,et al.  Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination , 2016, Nature Reviews Clinical Oncology.

[27]  J. Mirjolet,et al.  Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide. , 2016, Journal of medicinal chemistry.

[28]  L. Zitvogel,et al.  The oncolytic peptide LTX-315 triggers immunogenic cell death , 2016, Cell Death and Disease.

[29]  J. Taube,et al.  Antagonists of PD-1 and PD-L1 in Cancer Treatment. , 2015, Seminars in oncology.

[30]  G. Freeman,et al.  The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. , 2015, Clinical therapeutics.

[31]  E. Jaffee,et al.  PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors , 2015, Journal of immunotherapy.

[32]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[33]  J. Wolchok,et al.  Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy , 2014, Science Translational Medicine.

[34]  S. Russell,et al.  ONCOLYTIC VIROTHERAPY , 2012, Nature Biotechnology.

[35]  Takashi Nakamura,et al.  Noninvasive and efficient transdermal delivery of CpG-oligodeoxynucleotide for cancer immunotherapy. , 2011, Journal of controlled release : official journal of the Controlled Release Society.